Adhiratha Boonyasiri1,2, Elita Jauneikaite3,4, Lauren M Brinkac5,6, Chris Greco5, Kanokorn Lerdlamyong7, Teerawit Tangkoskul7, Kevin Nguyen5, Visanu Thamlikitkul8,7, Derrick E Fouts9. 1. Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. ab11915@ic.ac.uk. 2. NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College, London, UK. ab11915@ic.ac.uk. 3. NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College, London, UK. 4. Department of Infectious Disease Epidemiology, School of Public Health, Imperial College, London, UK. 5. J. Craig Venter Institute, Rockville, MD, USA. 6. Noblis, Reston, VA, USA. 7. Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 8. Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. 9. J. Craig Venter Institute, Rockville, MD, USA. dfouts@jcvi.org.
Abstract
BACKGROUND: Infections caused by carbapenemase-producing Enterobacteriaceae (CPE) have continually grown as a global public health threat, with significant mortality rates observed across the world. We examined the clinical data from patients with CPE infections and their outcomes, concentrating on Klebsiella pneumoniae isolates. We analysed the clinical information, performed antimicrobial susceptibility testing, and conducted molecular epidemiological and genomic analyses on the isolates to identify patterns in the data. METHODS: The clinical characteristics of 33 hospitalised patients with confirmed CPE, including patient-related factors associated with the development of CPE infections, were examined. Patients were divided according to whether they were "colonised" or "infected" with CPE and by the timing and frequency of their rectal swab collections, from which 45 swabs were randomly selected for analysis. CPE isolates were purified, and antimicrobial susceptibility tests performed. Whole genome sequences of these isolates were determined and analysed to compute bacterial multilocus sequence types and plasmid replicon types, infer phylogenetic relationships, and identify antimicrobial resistance and virulence genes. RESULTS: Altogether, 88.9% (40/45) of the CPE isolates were K. pneumoniae. The most abundant carbapenemase gene family in the K. pneumoniae isolates (33/39) was blaOXA-232, with blaNDM-1 additionally identified in 19 of them. All CPE isolates carrying either blaOXA-232 or blaNDM-1 were resistant to meropenem, but only 40 from 45 were susceptible to colistin. Among the CPE-infected patients (n = 18) and CPE-colonised patients who developed CPE infections during the study (n = 3), all but one received standard colistin-based combination therapy. Phylogenetic analysis revealed the polyclonal spread of carbapenemase-producing K. pneumoniae (CPKP) within the patient population, with the following two major subclades identified: ST16 (n = 15) and ST231 (n = 14). CPKP-ST231 had the highest virulence score of 4 and was associated with primary bacteraemia. The siderophores yersiniabactin and aerobactin, considered to be important virulence factors, were only identified in the CPKP-ST231 genomes. CONCLUSIONS: This study has revealed the genomic features of colonising CPE isolates, focusing on antimicrobial resistance and virulence determinants. This type of multi-layered analysis can be further exploited in Thailand and elsewhere to modify the regimes used for empirical antibiotic treatment and improve the management strategies for CPE infections in hospitalised patients.
BACKGROUND:Infections caused by carbapenemase-producing Enterobacteriaceae (CPE) have continually grown as a global public health threat, with significant mortality rates observed across the world. We examined the clinical data from patients with CPE infections and their outcomes, concentrating on Klebsiella pneumoniae isolates. We analysed the clinical information, performed antimicrobial susceptibility testing, and conducted molecular epidemiological and genomic analyses on the isolates to identify patterns in the data. METHODS: The clinical characteristics of 33 hospitalised patients with confirmed CPE, including patient-related factors associated with the development of CPE infections, were examined. Patients were divided according to whether they were "colonised" or "infected" with CPE and by the timing and frequency of their rectal swab collections, from which 45 swabs were randomly selected for analysis. CPE isolates were purified, and antimicrobial susceptibility tests performed. Whole genome sequences of these isolates were determined and analysed to compute bacterial multilocus sequence types and plasmid replicon types, infer phylogenetic relationships, and identify antimicrobial resistance and virulence genes. RESULTS: Altogether, 88.9% (40/45) of the CPE isolates were K. pneumoniae. The most abundant carbapenemase gene family in the K. pneumoniae isolates (33/39) was blaOXA-232, with blaNDM-1 additionally identified in 19 of them. All CPE isolates carrying either blaOXA-232 or blaNDM-1 were resistant to meropenem, but only 40 from 45 were susceptible to colistin. Among the CPE-infectedpatients (n = 18) and CPE-colonised patients who developed CPE infections during the study (n = 3), all but one received standard colistin-based combination therapy. Phylogenetic analysis revealed the polyclonal spread of carbapenemase-producing K. pneumoniae (CPKP) within the patient population, with the following two major subclades identified: ST16 (n = 15) and ST231 (n = 14). CPKP-ST231 had the highest virulence score of 4 and was associated with primary bacteraemia. The siderophores yersiniabactin and aerobactin, considered to be important virulence factors, were only identified in the CPKP-ST231 genomes. CONCLUSIONS: This study has revealed the genomic features of colonising CPE isolates, focusing on antimicrobial resistance and virulence determinants. This type of multi-layered analysis can be further exploited in Thailand and elsewhere to modify the regimes used for empirical antibiotic treatment and improve the management strategies for CPE infections in hospitalised patients.
Authors: Mette V Larsen; Salvatore Cosentino; Simon Rasmussen; Carsten Friis; Henrik Hasman; Rasmus Lykke Marvig; Lars Jelsbak; Thomas Sicheritz-Pontén; David W Ussery; Frank M Aarestrup; Ole Lund Journal: J Clin Microbiol Date: 2012-01-11 Impact factor: 5.948
Authors: Christian G Giske; Inga Fröding; Chowdhury Mehedi Hasan; Agata Turlej-Rogacka; Mark Toleman; David Livermore; Neil Woodford; Timothy R Walsh Journal: Antimicrob Agents Chemother Date: 2012-02-21 Impact factor: 5.191
Authors: Kelly L Wyres; To N T Nguyen; Margaret M C Lam; Louise M Judd; Nguyen van Vinh Chau; David A B Dance; Margaret Ip; Abhilasha Karkey; Clare L Ling; Thyl Miliya; Paul N Newton; Nguyen Phu Huong Lan; Amphone Sengduangphachanh; Paul Turner; Balaji Veeraraghavan; Phat Voong Vinh; Manivanh Vongsouvath; Nicholas R Thomson; Stephen Baker; Kathryn E Holt Journal: Genome Med Date: 2020-01-16 Impact factor: 11.117
Authors: Tatiana Tatusova; Michael DiCuccio; Azat Badretdin; Vyacheslav Chetvernin; Eric P Nawrocki; Leonid Zaslavsky; Alexandre Lomsadze; Kim D Pruitt; Mark Borodovsky; James Ostell Journal: Nucleic Acids Res Date: 2016-06-24 Impact factor: 16.971
Authors: Kalyan D Chavda; Liang Chen; Derrick E Fouts; Granger Sutton; Lauren Brinkac; Stephen G Jenkins; Robert A Bonomo; Mark D Adams; Barry N Kreiswirth Journal: MBio Date: 2016-12-13 Impact factor: 7.867
Authors: Jessica Martin; Hang T T Phan; Jacqueline Findlay; Nicole Stoesser; Louise Pankhurst; Indre Navickaite; Nicola De Maio; David W Eyre; Giles Toogood; Nicolas M Orsi; Andrew Kirby; Nicola Young; Jane F Turton; Robert L R Hill; Katie L Hopkins; Neil Woodford; Tim E A Peto; A Sarah Walker; Derrick W Crook; Mark H Wilcox Journal: J Antimicrob Chemother Date: 2017-11-01 Impact factor: 5.790
Authors: Joseph D Lutgring; Wenming Zhu; Tom J B de Man; Johannetsy J Avillan; Karen F Anderson; David R Lonsway; Lori A Rowe; Dhwani Batra; J Kamile Rasheed; Brandi M Limbago Journal: Emerg Infect Dis Date: 2018-04 Impact factor: 6.883
Authors: Geetha Nagaraj; Varun Shamanna; Vandana Govindan; Steffimole Rose; D Sravani; K P Akshata; M R Shincy; V T Venkatesha; Monica Abrudan; Silvia Argimón; Mihir Kekre; Anthony Underwood; David M Aanensen; K L Ravikumar Journal: Clin Infect Dis Date: 2021-12-01 Impact factor: 9.079
Authors: Willames M B S Martins; Mei Li; Kirsty Sands; Michael H Lenzi; Edward Portal; Jordan Mathias; Priscila P Dantas; Roberta Migliavacca; James R Hunter; Eduardo A Medeiros; Ana C Gales; Mark A Toleman Journal: Emerg Microbes Infect Date: 2022-12 Impact factor: 7.163